Replies to post #191287 on Biotech Values

[DewDiligence]

EGRX’s 1Q15 10-Q contains the Treanda agreements with TEVA:

http://www.sec.gov/Archives/edgar/data/827871/000082787115000031/doc_116842003xvx2xcephalon.htm
http://www.sec.gov/Archives/edgar/data/827871/000082787115000031/doc_116846672xvx2xcephalon.htm
http://www.sec.gov/Archives/edgar/data/827871/000082787115000031/egrx_q1x2015new.htm

[ChikiTiny]

I agree that it can pay off big if the thinking is valid....for example buying ESPR after removal of partial clinical hold below 50 was the right decision even though stock had tripled previously.

[DewDiligence]

EGRX receives US patent on rapid-infusion formulation of Treanda:

http://finance.yahoo.com/news/patent-issued-eagle-pharmaceuticals-bendamustine-123000408.html

Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. Patent No. 9,034,908, which pertains to the use of the bendamustine hydrochloride (HCl) formulation administered in a 50mL bag within ten minutes (the “rapid infusion” product). The patent issued today expires in March 2033.

This is the product that Teva licensed in Feb 2015 (#msg-110943484). The product has a PDUFA date of 12/13/15.